Iksuda Therapeutics Email Format

Biotechnology ResearchEngland, United Kingdom11-50 Employees

Iksuda Therapeutics is a Newcastle upon Tyne-based biotechnology company developing antibody-drug conjugates (ADCs) for cancer. It is building a pipeline of ADCs aimed at delivering strong anti-tumor activity with a favorable therapeutic index in difficult-to-treat cancers. The company prioritizes matching the best ADC to each target or tumor subtype rather than pursuing a technology-led approach, and its ADCs are engineered for tumor-selective payload release and activation to optimize efficacy while enhancing patient safety. 

Its activities extend to collaborations with other players in the ADC space, and public updates reference ongoing clinical exploration. In 2026, the company disclosed early Phase 1 data on IKS014, a HER2-directed ADC, from oesophageal cancer studies presented at the ASCO Gastrointestinal Cancers Symposium.

Sign up for free to view info

Company overview Employee directory